GLP-1 Drugs and Pregnancy: Key Science, Contraception Considerations, and New Guidelines

Summary

In this Short Wave episode, NPR examines how GLP-1 drugs used for weight loss and diabetes affect pregnancy and fertility. Amy Valent, an OB-GYN, describes how these medications have surged in popularity and how patients and clinicians are grappling with fertility and pregnancy decisions as GLP-1 use becomes widespread. The show highlights new guidance from the American College of Obstetricians and Gy Gynecologists (ACOG) on GLP-1 use and pregnancy, to help providers counsel patients. It also touches on contraception considerations, potential insulin resistance in PCOS, and nutritional concerns during pregnancy while on GLP-1 therapy. The episode emphasizes the need for pregnancy-inclusive research and thoughtful clinical guidance as GLP-1 therapies continue to evolve.

• Glp-1 drugs may affect oral contraceptive efficacy, especially tirzepatide, prompting recommendations for additional contraception methods.
• PCOS and related fertility issues can improve with GLP-1 therapies through better metabolic control and ovulation onset.
• ACOG issued guidance in October advising stopping GLP-1 drugs before or during pregnancy, with timing depending on the drug’s half life.
• Weight rebound after stopping GLP-1 therapy and nutritional considerations during pregnancy are important factors in counseling.

GLP-1 Drugs in the Context of Pregnancy

The podcast centers on GLP-1 receptor agonists such as Ozempic (semaglutide), Mounjaro (tirzepatide), and Zepbound, tracing their rapid rise in use for weight management and diabetes. Amy Valent, an obstetrician-gynecologist at Oregon Health and Science University, explains how GLP-1s have entered a frontier in reproductive health, including a social media-anchored narrative around unplanned pregnancies while on these medications. The interview underscores the complexity of managing GLP-1 therapy across pregnancy planning, gestation, and postpartum periods, and it points to a growing need for pregnancy-inclusive clinical research.

Contraception and GLP-1 Interactions

The discussion highlights evidence that GLP-1 drugs can alter the body’s absorption of orally administered contraceptives. Tirzepatide, in particular, has been associated with decreased contraceptive efficacy in some patients. The guest suggests using barrier methods or non-oral contraception such as IUDs or implants, especially during dose changes or when starting tirzepatide. The conversation emphasizes that drug half-life differences require individualized planning with providers, and it reflects the clinical need to mitigate unintended pregnancies when GLP-1 therapy is ongoing.

Fertility, PCOS, and Pre-pregnancy Health

The episode discusses how GLP-1s can offer new therapeutic opportunities for people with polycystic ovarian syndrome (PCOS), previously known as PMOS in the transcript, who often face insulin resistance and fertility challenges. Valent notes that elevated sugars before pregnancy are linked to increased risks of birth defects and miscarriage. By improving glycemic control and promoting ovulation, GLP-1s can help optimize pre-pregnancy health and potentially support safer pregnancy outcomes. The narrative also acknowledges the broader health benefits GLP-1s may provide to diverse patient groups beyond PCOS, reinforcing the idea that better metabolic health before conception contributes to pregnancy safety and health outcomes.

ACOG Guidelines and Clinical Practice

The core focus of the show is the October release of guidance from the American College of Obstetricians and Gynecologists to help OB GYNs counsel patients facing decisions about GLP-1 use around pregnancy. Valent contributed to these recommendations, which address when to discontinue GLP-1 therapy, how to manage potential weight rebound, and the safety considerations for fetal development and placental function. The episode reflects on the challenges of aligning rapid therapeutic development with pregnancy-specific safety data, highlighting why the guidelines are an important step in standardizing care across a rapidly changing therapeutic landscape.

Nutrition, Weight, and Practical Counseling

Nutritional considerations are emphasized because GLP-1s can blunt appetite, potentially affecting nutrient intake during pregnancy. Valent explains the need to monitor eating patterns to ensure essential nutrients are provided to support fetal growth. The transcript also notes the tension between stopping GLP-1 therapy to improve pregnancy safety and the potential health risks of continuing therapy during pregnancy. Counseling emphasizes balancing maternal health, weight management, and fetal well-being while navigating evolving guidelines and patient preferences.

Broader Implications and Future Research

Overall, the podcast underscores a broader theme: many therapeutics are not studied in pregnant populations at the time of approval, so real-world data and proactive guidelines are essential. It calls for more research that includes pregnant people and considers pharmacokinetic interactions with pregnancy physiology, placental transfer, and maternal nutrition. The episode closes with optimism about continuing innovations in GLP-1 therapies and a commitment to ensuring patient safety through evidence-based guidance.